Unternehmens-Profil
AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 202,65 USD· Stand 07.05.2026
News · ABBVIE INC
- 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
- AbbVie to Present at the Bank of America Securities Healthcare Conference
- Want Reliable Dividend Income in May? These 2 Stocks Deliver
- Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
- AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®